<DOC>
	<DOCNO>NCT01455584</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) HM781-36B continuously .</brief_summary>
	<brief_title>Clinical Trial Determine MTD HM781-36B Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Besides main objective , 4 objective follow : 1 . To determine dose-limiting toxicity ( DLT ) HM781-36B 2 . To determine Maximum Tolerated Dose ( MTD ) HM781-36B 3 . To determine effect food pharmacokinetics dose HM781-36B continuously 4 . To evaluate anticancer activity HM781-36B patient advance solid malignancy</detailed_description>
	<criteria>1 . Histologically cytologically confirm advanced solid tumor 2 . Patients experience progressive disease despite conventional anticancer therapy . Patients expect effective treatment prolong survival conventional anticancer therapy 3 . Previous chemotherapy , radiotherapy surgical operation allow discontinue least 4 week prior D0 adverse event resolve 4 . Aged â‰¥19 5 . Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 6 . A life expectancy great 12 week 7 . Adequate bone marrow , renal liver function . 8 . Subjects must provide write informed consent prior performance study specific procedure assessment , must willing comply treatment follow assessment procedures 1 . Patients hematopoietic malignancy , uncontrolled infection , CNS metastasis . 2 . Patients undergone hematopoietic stem cell transplantation ( HSCT ) candidate plan HSCT 3 . Patients GI malabsorption difficulty take oral medication 4 . Patients psychiatric congenital disorder 5 . Subjects , investigator 's opinion , treat per protocol due functional impairment 6 . Pregnant breastfeeding patient ; Women childbearing potential without adequate contraception ( Men must use adequate contraception . )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HM781-36B</keyword>
</DOC>